EDAP TMS SA (NASDAQ:EDAP) will release the third quarter earnings for 2009 on Tuesday, November 17 before the market opens. The company will host a conference call at 8:30 am ET to review the financial results. Interested parties may join the call by dialing877.407.4134 or 201.689.8430 for international callers. The conference ID is 337006. To hear a replay of the conference, listeners must dial 877.660.6853 or 201.612.7415 for international callers, and provide the account number, 356, and the event ID number, 337006. A webcast of the presentation will also be available online at www.edap-tms.com on the Investor Relations page.
Best Damn Penny Stocks, a leading financial publication, is pleased to alert investors of stocks on the move. Sign Up for our Free Stock Newsletter
EDAP TMS S.A. (EDAP) is a holding company that develops, produces and markets minimally invasive medical devices, mainly for urological diseases through two divisions: High Intensity Focused Ultrasound (HIFU) Division and Urology Devices and Services (UDS) Division. The Company’s HIFU and UDS divisions operate in Europe, the Americas, Asia and the rest of the world. The HIFU division is engaged in the development, manufacturing and marketing of medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications. The UDS division is engaged in the development, marketing, manufacturing and servicing of medical devices for the minimally invasive diagnosis or treatment of urological disorders, mainly urinary stones, and other clinical indications.
Sign up for the free Best Damn Penny Socks newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website
About Best Damn Penny Stocks
Best Damn Penny Stocks is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We also track small cap companies that are on the brink of a financial breakout. To feature a company on our web site please contact us at the email listed below.
Please click here to read the full disclaimer
